<DOC>
	<DOCNO>NCT01646268</DOCNO>
	<brief_summary>The primary objective demonstrate Rotigotine transdermal patch efficacious Chinese subject early-stage idiopathic Parkinson 's disease .</brief_summary>
	<brief_title>Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson 's Disease Patients</brief_title>
	<detailed_description>The study include maximum 4-week Screening Period , maximum 4-week Titration Period early-stage Parkinson 's disease 24-week Maintenance Period , maximum 6-day De-escalation Period 30-day Safety Follow-Up Period . The maximum study duration individual subject early-stage Parkinson 's disease 36 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>An Independent Ethics Committee ( IEC ) approve write informed consent sign date subject legal representative Subject/legal representative consider reliable capable adhere protocol , visit schedule study medication intake accord judgment investigator Subject Idiopathic Parkinson 's Disease ≤5 year ' duration , define cardinal sign , Bradykinesia , plus presence least 1 follow : rest tremor , rigidity , impairment postural reflex , without know suspected cause Parkinsonism Subject Hoehn &amp; Yahr stage ≤3 Subject male female age ≥30 year Screening ( Visit 1 ) Subject Mini Mental State Examination ( MMSE ) score ≥25 Subject Unified Parkinson 's Disease Rating Scale ( UPDRS ) motor score ( Part III ) ≥10 Baseline ( Visit 2 ) If subject receive Anticholinergic agent ( eg , Benztropine , Trihexyphenidyl , Parsitan , Procyclidine , Biperiden ) , monoamine oxidase ( MAO ) B inhibitor ( eg , Selegiline ) , Nmethyldaspartate ( NMDA ) antagonist ( eg , Amantadine ) , he/she must stable dose least 28 day prior Baseline ( Visit 2 ) maintain dose duration study Subject previously participate study subject previously receive study medication investigation study Subject participate another study investigational drug do within 28 day prior Baseline Visit ( Visit 2 ) Subject history significant skin hypersensitivity adhesive transdermal preparation recent unresolved contact Dermatitis Subject lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening ( Visit 1 ) Subject atypical Parkinson 's syndrome ( ) due drug ( eg , Metoclopramide , Flunarizine ) , metabolic neurogenetic disorder ( eg , Wilson 's Disease ) , Encephalitis , Cerebrovascular Disease , Degenerative Disease ( eg , progressive Supranuclear Palsy ) Subject history Pallidotomy , Thalamotomy , deep brain stimulation , fetal tissue transplant Subject dementia , active psychosis hallucination , severe depression Subject receive therapy dopamine agonist either concurrently do within 28 day prior Baseline Visit ( Visit 2 ) Subject receive therapy L dopa/carbidopa and/or Ldopa/benserazide within 28 day Baseline ( Visit 2 ) receive Ldopa/carbidopa and/or Ldopa/benserazide 6 month since diagnosis Subject receive therapy 1 follow drug either concurrently within 28 day prior Baseline ( Visit 2 ) : Alphamethyl dopa , Metoclopramide , Reserpine , Neuroleptics ( except specific atypical neuroleptic : Olanzapine , Ziprasidone , Aripiprazole , Clozapine , Quetiapine ) , MAOA inhibitor , Methylphenidate , Amphetamine Subject currently receive central nervous system ( CNS ) active therapy ( eg , sedative , hypnotic , antidepressant , anxiolytic ) , unless dose stable least 28 day prior Baseline Visit ( Visit 2 ) likely remain stable duration study Subject current diagnosis Epilepsy , history seizure adult , history stroke , transient ischemic attack within 1 year prior Screening ( Visit 1 ) Subject clinically relevant hepatic dysfunction ( defined total bilirubin &gt; 2.0 mg/dL alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great 2 time upper limit reference range ) Subject clinically relevant renal dysfunction ( serum creatinine &gt; 2.0 mg/dL [ &gt; 178 umol/L ] ) Subject clinically relevant cardiac dysfunction ( cardiac disorder opinion investigator would put subject risk clinically relevant arrhythmia ) and/or myocardial infarction within last 12 month Subject QT interval correct heart rate accord Bazett 's formula ( QTcB ) ≥500 ms Screening ( Visit 1 ) Subject history symptomatic ( asymptomatic ) orthostatic hypotension decrease systolic blood pressure ( SBP ) supine stand position ≥20 mmHg ≥10 mmHg diastolic blood pressure ( DBP ) 1 3 minute within 28 day prior Baseline Visit ( Visit 2 ) , SBP le 105 mmHg study entry Subject evidence impulse control disorder ( ICD ) Screening ( Visit 1 ) Subject history know intolerance/hypersensitivity follow Antiemetics ; Domperidone , Trimethobenzamide , Ondansetron , Tropisetron , Granisetron , Glycopyrrolate Subject history chronic alcohol drug abuse within last 5 year Subject pregnant nursing , childbearing potential ( ) surgically sterile ( ii ) use adequate birth control method ( include least double barrier method ) ( iii ) sexually abstinent ( iv ) least 2 year postmenopausal Subject clinically relevant medical condition , psychiatric condition , laboratory abnormality , would judgment investigator , interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro phase 3</keyword>
	<keyword>Early phase</keyword>
	<keyword>Idiopathic Parkinson 's Disease</keyword>
</DOC>